Tecarfarin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tecarfarin
- DrugBank Accession Number
- DB12823
- Background
Tecarfarin has been used in trials studying the prevention of Thrombosis and Thromboembolism.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 460.328
Monoisotopic: 460.074542529 - Chemical Formula
- C21H14F6O5
- Synonyms
- Tecarfarin
- External IDs
- Ati 5923
- ATI-5923
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Tecarfarin. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Tecarfarin. Dexmethylphenidate The serum concentration of the active metabolites of Tecarfarin can be increased when Tecarfarin is used in combination with Dexmethylphenidate. Diazoxide The serum concentration of Tecarfarin can be increased when it is combined with Diazoxide. Doxycycline The therapeutic efficacy of Tecarfarin can be increased when used in combination with Doxycycline. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Coumarins and derivatives
- Sub Class
- Hydroxycoumarins
- Direct Parent
- 4-hydroxycoumarins
- Alternative Parents
- Benzoic acid esters / 1-benzopyrans / Benzoyl derivatives / Pyranones and derivatives / Vinylogous acids / Heteroaromatic compounds / Lactones / Carboxylic acid esters / Oxacyclic compounds / Organooxygen compounds show 4 more
- Substituents
- 1-benzopyran / 4-hydroxycoumarin / Alkyl fluoride / Alkyl halide / Aromatic heteropolycyclic compound / Benzenoid / Benzoate ester / Benzoic acid or derivatives / Benzopyran / Benzoyl show 16 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WN1479YT50
- CAS number
- 867257-26-9
- InChI Key
- QFLNTQDOVCLQKW-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
- IUPAC Name
- 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate
- SMILES
- CC(OC(=O)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F
References
- General References
- Not Available
- External Links
- PubChem Compound
- 54718618
- PubChem Substance
- 347828992
- ChemSpider
- 26467760
- ChEMBL
- CHEMBL2105664
- Wikipedia
- Tecarfarin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Unknown Status Treatment Thromboembolism / Thrombosis 1 2 Completed Treatment Atrial Fibrillation 1 2, 3 Unknown Status Treatment Atrial Fibrillation / Atrial Flutter / Cardiomyopathy / Myocardial Infarction / Venous Thromboembolism Diseases 1 1 Completed Basic Science Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin 1 1 Unknown Status Basic Science Healthy Chinese Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0026 mg/mL ALOGPS logP 4.71 ALOGPS logP 5.26 Chemaxon logS -5.2 ALOGPS pKa (Strongest Acidic) 5.13 Chemaxon pKa (Strongest Basic) -6.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 72.83 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 99.73 m3·mol-1 Chemaxon Polarizability 37.11 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0001900000-26b53a3e412d4bf14513 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0000900000-1f719bb4f8b28e235023 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-01ta-0190600000-f83bb01e995cc2f85856 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-2003900000-472e8b4e6c86f5d1fa0c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00b9-2971100000-b2e2728e1236013e05cf Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0bt9-1009100000-e9591e71e57ed303ce25 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 193.11513 predictedDeepCCS 1.0 (2019) [M+H]+ 195.47314 predictedDeepCCS 1.0 (2019) [M+Na]+ 201.62366 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 00:31 / Updated at February 21, 2021 18:54